NCT00537901已完成不适用
First-Line Bevacizumab and Chemotherapy in Metastatic Cancer of the Colon or Rectum - International Study
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 100
- 主要终点
- Effectiveness
研究概览
简要总结
First-Line Bevacizumab and Chemotherapy in Metastatic Cancer of the Colon or Rectum
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with metastatic cancer of colon or rectum
排除标准
- 未提供
结局指标
主要结局
Effectiveness
时间窗: overall
次要结局
- Quality of life(overall)
研究者
Dr. Naeem A. Chaudhri
Principal Investigator
King Faisal Specialist Hospital & Research Center
相似试验
进行中（未招募）
不适用
First-line Bevacizumab and Chemotherapy in Metastatic Cancer of the Colon or Rectum. An Expanded Access Program.metastatic colo-rectal carcinomaMedDRA version: 6.1Level: PTClassification code 10061045EUCTR2004-000315-26-ITROCHE1,500
进行中（未招募）
1 期
First-line Bevacizumab and Chemotherapy in Metastatic Cancer of the Colon or Rectum. An Expanded Access Program. - First BEATMetastatic cancer of the colon or rectum.EUCTR2004-000315-26-SKF.Hoffmann-La Roche Ltd.2,000
进行中（未招募）
不适用
First-line Bevacizumab and Chemotherapy in Metastatic Cancer of the Colon or Rectum. An Expanded Access Program. - First BEATMetastatic cancer of the colon or rectum.EUCTR2004-000315-26-HUF. Hoffmann-La Roche Ltd.2,000
进行中（未招募）
1 期
First-line Bevacizumab and Chemotherapy in Metastatic Cancer of the Colon or Rectum.Metastatic cancer of the colon or rectum.EUCTR2004-000315-26-ESF. Hoffmann-La Roche Ltd.2,000
招募中
3 期
Bevacizumab-based Chemotherapy Adapted to Bevacizumab Pharmacokinetics in 1st-line TreatmentUnresectable Metastatic Colorectal CancerNCT06642844University Hospital, Tours244